1. Digital biomarkers for Alzheimer's disease: the mobile/ wearable devices opportunity.
- Author
-
Kourtis LC, Regele OB, Wright JM, and Jones GB
- Abstract
Alzheimer's Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping., Competing Interests: Competing interests: L.C.K., O.B.R., and J.G.W. have been employees at Eli Lilly and Company when part of this work was created. L.C.K. is currently a consultant to Evidation Health. The remaining authors declare no competing interests.
- Published
- 2019
- Full Text
- View/download PDF